» Articles » PMID: 26286747

MicroRNA-542-3p Suppresses Tumor Cell Invasion Via Targeting AKT Pathway in Human Astrocytoma

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2015 Aug 20
PMID 26286747
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The molecular mechanism underlying constitutive activation of AKT signaling, which plays essential roles in astrocytoma progression, is not fully characterized. Increasing numbers of studies have reported that microRNAs are involved in the malignant behavior of astrocytoma cells via directly targeting multiple oncogenes or tumor suppressors. Here, we found that microRNA (miR)-542-3p expression was decreased in glioblastoma cell lines and astrocytoma tissues, and reduced levels of miR-542-3p expression correlated with high histopathological grades and poor prognosis of astrocytoma patients. Exogenous miR-542-3p suppressed glioblastoma cell invasion through not only targeting AKT1 itself but also directly down-regulating its two important upstream regulators, namely, integrin-linked kinase and PIK3R1. Notably, overexpressing miR-542-3p decreased AKT1 phosphorylation and directly and indirectly repressed nuclear translocation and transactivation activity of β-catenin to exert its anti-invasive effect. Furthermore, the miR-542-3p expression level negatively correlated with AKT activity as well as levels of integrin-linked kinase and PIK3R1 in human astrocytoma specimens. These findings suggest that miR-542-3p acts as a negative regulator in astrocytoma progression and that miR-542-3p down-regulation contributes to aberrant activation of AKT signaling, leaving open the possibility that miR-542-3p may be a potential therapeutic target for high grade astrocytoma.

Citing Articles

The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma.

Bora Yildiz C, Du J, Mohan K, Zimmer-Bensch G, Abdolahi S Epigenomics. 2025; 17(2):125-140.

PMID: 39829063 PMC: 11792803. DOI: 10.1080/17501911.2024.2442297.


Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.

Norollahi S, Yousefi B, Nejatifar F, Yousefzadeh-Chabok S, Rashidy-Pour A, Samadani A J Egypt Natl Canc Inst. 2024; 36(1):33.

PMID: 39465481 DOI: 10.1186/s43046-024-00240-4.


Interplay of miR-542, miR-126, miR-143 and miR-26b with PI3K-Akt is a Diagnostic Signal and Putative Regulatory Target in HPV-Positive Cervical Cancer.

Rahimi-Moghaddam A, Ghorbanmehr N, Gharbi S, Nili F, Korsching E Biochem Genet. 2024; .

PMID: 38849709 DOI: 10.1007/s10528-024-10837-y.


Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma.

Zeng C, Li H, Liang W, Chen J, Zhang Y, Zhang H Endocrine. 2023; 83(1):127-141.

PMID: 37541962 DOI: 10.1007/s12020-023-03468-7.


Role and Dysregulation of miRNA in Patients with Parkinson's Disease.

Salemi M, Marchese G, Lanza G, Cosentino F, Salluzzo M, Schillaci F Int J Mol Sci. 2023; 24(1).

PMID: 36614153 PMC: 9820759. DOI: 10.3390/ijms24010712.


References
1.
Kahn M . Can we safely target the WNT pathway?. Nat Rev Drug Discov. 2014; 13(7):513-32. PMC: 4426976. DOI: 10.1038/nrd4233. View

2.
He T, Qi F, Jia L, Wang S, Song N, Guo L . MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J Pathol. 2014; 232(5):499-508. DOI: 10.1002/path.4324. View

3.
Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

4.
Holland E, Celestino J, Dai C, Schaefer L, Sawaya R, Fuller G . Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000; 25(1):55-7. DOI: 10.1038/75596. View

5.
Sonoda Y, Ozawa T, Aldape K, Deen D, Berger M, Pieper R . Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001; 61(18):6674-8. View